南京市人群DNA修复基因XRCC1多态性与肺癌易感性的关系  

Relationship between Polymorphisms of DNA Repair Gene XRCC1 and Susceptibility to Lung Cancer in Nanjing Population

作　　者：宋雅辉[1] 尹立红[1] 浦跃朴[1] 梁戈玉[1] 崔红梅[1] 

机构地区：[1]东南大学公共卫生学院,江苏南京210009

出　　处：《环境与职业医学》2004年第1期18-21,共4页Journal of Environmental and Occupational Medicine

基　　金：国家自然科学基金 (编号 :30170791);江苏省社会发展基金(编号 :BS2000034)

摘　　要：[目的]研究碱基切除修复基因XRCC1多态性与南京市人群肺癌易感性的关系。[方法]采用配对病例_对照研究 ,收集南京籍原发性肺癌患者104例为病例组 ,同时按1:1配对选择非肿瘤、非呼吸道疾病患者104例为对照组 ,并进行流行病学调查。应用PCR_RFLP方法分析了病例组和对照组的XRCC1基因Arg194Trp和Arg399Gln两个位点的多态性 ,比较不同基因型与肺癌易感性的关系 ,以及基因多态性与吸烟之间对肺癌易感性的交互作用。[结果]携带399Gln等位基因的个体其肺癌危险性增高 (OR=1.790 ,95 %CI=1.033～3.103 ,P=0.038) ,且主要增加患鳞癌的危险 (OR=2.426 ,95 %CI=1.123～5.237,P=0.023);并与吸烟指数≥20的有一定的协同作用 (OR=2.536 ,95 %CI=1.043～6.165)。Arg194Trp与肺癌危险性之间未见显著性相关 (OR=1.040 ,95%CI=0.600～1.805)。[结论]碱基切除修复基因XRCC1的多态性可能会对肺癌易感性产生影响 。ObjectiveThe current study analyzed the polymorphisms of DNA repair gene XRCC1in Nanjing population and reˉlationship between genetic variations and susceptibility to lung cancer.[Methods] A case-control study of104patients with lung cancer and104cancer-free subjects as a control group(matched for age±5years and sex)was conducted to detect XRCC1polymorphisms at both Arg194Trp and Arg399Gln loci.Genotypes were analyzed by PCR-based restriction fragment length polymorphism(RLFP)techˉniques.[Results] It showed that an increase in the susceptibility to lung cancer was associated with the399Gln allele(either the heterozygous Arg/Gln or the homozygous Gln/Gln genotypes,OR=1.790,95%CI=1.033～3.103,P=0.038).The399Gln allele might relate to the risk of squamous cell carcinoma of the lung(OR=2.426,95%CI=1.123～5.237,P=0.023)and have synerˉgistic effect with the smoking.No association was observed between the XRCC1Arg194Trp polymorphism and susceptibility to lung cancer.[Conclusion] The results demonstrated that genetic polymorphism of XRCC1DNA repair gene might contribute to the susˉceptibility to lung cancer and have synergistic effect with the smoking.

关 键 词：南京 DNA修复基因 XRCC1基因 基因多态性 肺癌 遗传易感性 

分 类 号：R734.2[医药卫生—肿瘤] R730.231[医药卫生—临床医学]